
News|Articles|April 21, 2025
AUA 2025: What to watch for in urologic oncology
Fact checked by: Hannah Clarke
We preview several noteworthy P2 presentations in the urologic oncology space.
Advertisement
Advertisement
The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking place at the Venetian Las Vegas from April 26-29 (and preceded by the AUA Innovation Nexus on April 25), the meeting will feature scientific abstracts, lectures, Crossfire Debates, the P2s: Practice-changing Paradigm-shifting Clinical Trials in Urology, and much more. In this article, we preview several noteworthy P2 presentations in the urologic oncology space. You can follow Urology Times’ coverage of the meeting
Related to this article

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.

Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Advertisement
Advertisement

